Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2015 (Events reported March 2–3, 2015)
Business Focus: Development of Neutrolin® catheter lock solution.
Key Financial Metrics and Agreements
This filing details a material definitive agreement rather than periodic financial results. Key financial terms include:
- Backstop Financing: Agreement with Manchester Securities Corp. to lend up to $4,500,000, reduced by gross proceeds from warrant exercises prior to April 30, 2015. The loan is capped at $3,000,000.
- Note Terms: Unsecured senior obligation with a 6.0% annual interest rate and a five-year term. Prepayment allowed after one year.
- Conversion Features: The note is convertible into common stock at the lower of 80% of the closing price or 80% of the seven-day volume-weighted average price prior to issuance.
- Warrant Issuance: Issued a new warrant for 200,000 shares at $7.00/share (5-year term) and extended an existing warrant for 390,720 shares at $3.4375/share to March 24, 2016.
- Liquidity Status: The filing does not provide specific cash balance or liquidity metrics, only the availability of the new credit facility.
Material Changes and Corporate Actions
- Listing Compliance: Regained compliance with NYSE MKT listing standards as of February 26, 2015, qualifying for the market capitalization exception after previously failing to meet standards.
- Strategic Advisory: Retained Evercore Group, L.L.C. to explore strategic alternatives to accelerate product development and maximize shareholder value.
- Warrant Extension: Extended the expiration date of publicly traded warrants (issued in 2010) to April 30, 2015, to allow time for resale registration.
- Board Representation: Granted Manchester Securities Corp. the right to appoint up to two Board members or have two non-voting observers.
Guidance, Risks, and Contingencies
Management Commentary: The company is actively pursuing strategic alternatives and securing financing to support the global development of Neutrolin®.
Risks and Contingencies:
- Ownership Limitations: Manchester Securities Corp. is prohibited from exercising warrants or converting the note if it would result in beneficial ownership exceeding 9.99% of outstanding shares (waivable with 61 days' notice).
- Financing Conditions: Access to the backstop loan is subject to customary conditions and the timing of warrant exercises.
- Dilution: The conversion of the note and exercise of warrants will result in the issuance of additional common stock, subject to the 9.99% cap.
Investor Verification Checklist
- Verify the current market capitalization to confirm continued compliance with NYSE MKT listing standards.
- Monitor the status of the resale registration for the 2010 bridge investor warrants.
- Track the progress of strategic alternatives being explored with Evercore Group, L.L.C.
- Review the specific terms of the convertible note (Exhibit 4.4) and backstop agreement (Exhibit 10.1) for detailed covenants.
- Assess the potential dilution impact of the new warrant and the potential note conversion.